Skip to main content
. 2017 Feb 15;2(2):554–562. doi: 10.1021/acsomega.6b00518

Figure 4.

Figure 4

(A) Percentage of live MRSA, when superbugs are captured by (i) anti-MRSA-antibody-attached fluorescent CD nanoparticles, (ii) anti-PSMA-antibody-attached fluorescent magneto-CD nanoparticles, and (iii) pardaxin-conjugated anti-PSMA-antibody-attached fluorescent magneto-CD nanoparticles. (B) Percentage of colonies of Salmonella DT104 compared with the control after capture by (i) anti-Salmonella-antibody-attached fluorescent CD nanoparticles, (ii) anti-Salmonella-antibody-attached fluorescent magneto-CD nanoparticles, and (iii) pardaxin-conjugated anti-Salmonella-antibody-attached fluorescent magneto-CD nanoparticles. (C,D) Agar plates of superbugs incubated (C) after being captured by a mixture of anti-MRSA-antibody-attached red fluorescent magneto-CD nanoparticles and anti-Salmonella-antibody-attached blue fluorescent magneto-CD nanoparticles and (D) after being captured by a mixture of pardaxin antimicrobial peptides-conjugated anti-MRSA-antibody-attached red fluorescent magneto-CD nanoparticles and pardaxin antimicrobial peptide-conjugated anti-Salmonella-antibody-attached blue fluorescent magneto-CD nanoparticles. (E) Plot shows how the percentage of live MRSA varies with the dosage level of pardaxin antimicrobial peptides.